C arotid artery disease is one of the main causes of stroke, apart from other cardiac causes or disease of the brain itself. About 80% of all strokes are ischemic and approximately 25-50% of these are caused by an unstable carotid artery plaque.
of the carotid arteries that were studied. The progression of ICA stenosis correlated with these events, but baseline ICA stenosis was not a significant predictor.
Three treatments for this problem are (1) medical therapy (2) carotid stenting (CS) and (3) carotid endarterectomy (CE). CE, surgical removal of the carotid atherosclerotic plaque, has formed the mainstay of surgical treatment. Endovascular angioplasty (with/ without stenting) for carotid stenosis, less invasive technique for carotid artery revascularization, has been proposed as a viable alternative to carotid endarterectomy. Current guidelines for CE in symptomatic carotid stenosis are based on two randomized; controlled trials, the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST), both from the 1990s. [5] [6] [7] In both trials, the degree of stenosis, estimated from a catheter angiogram, was the major criterion for recommending CE. According to these trials, the benefit from CE is greatest in patients with 70-99% stenosis with a 5-year absolute risk reduction of 15.3%, less, only 7.8% in those with 50-70% stenosis and minimal in those with <50% stenosis. Since then there were several clinical trials published.
The objectives of this review are (1) to provide evidences of benefit/risk of each treatment and (2) to create recommendation for patients.
Five different aspects should be considered as to the treatment of patients with carotid disease:
1. Neurological symptomatology [patients are classified as symptomatic if they have a carotid distribution transient ischemic attack (TIA: a brief episode of neurological dysfunction caused by a focal disturbance of brain or retinal ischemia, with clinical symptoms typically lasting less than 1 hour, and without evidence of infarction 8 ), or non-disabling stroke in the preceding 6 months (originally 4 months in NASCET)].
2. Degree of carotid stenosis [NASCET calculated the degree of stenosis using the site of maximal narrowing as the numerator, divided by the distal ICA diameter where the vessel walls became parallel and beyond any area of post-stenotic dilatation. 9 ECST calculated the degree of stenosis using the diameter at the site of maximal narrowing divided by the estimated diameter of the normal carotid bulb. 10 This means for a given level of stenosis, the percentage narrowing would be lower using the NASCET method compared to the ECST method. For example, a NASCET 70% stenosis corresponds to an 82% ECST stenosis. 11, 12 The recommendation is that carotid duplex should be a bilateral scan and include a basic assessment of the vertebral arteries. All results and calculations to refer to the NASCET method of measurement. Traditional imaging methods of carotid artery disease include angiography, duplex ultrasound and computed tomography angiography (CTA). These methods mainly focus on anatomic features of the plaque; however, some techniques are also able to detect morphologic characteristics of plaque vulnerability such as ulceration, a large lipid or necrotic core and a thin fibrous cap. Angiography was the gold standard in the NASCET and ECST to determine degree of stenosis. Duplex ultrasonography and CTA are also being used to determine the degree of stenosis in carotid artery disease. With regard to plaque morphology, several studies have compared the imaging results to histopathological findings as the gold standard. Angiography was able to detect ulceration with a sensitivity and specificity of approximately 45% and 75%, respectively. 13, 14 CTA has also shown to identify plaque ulceration, calcification and lipid cores with an overall agreement of about 75% between CTA findings and histology. 15, 16 Among the current clinically available imaging modalities, MRI seems the most accurate method to image plaque morphology in carotid artery disease. Various advanced imaging methods are available, such as high-resolution magnetic resonance imaging, single photon emission computed tomography (SPECT), positron emission tomography (PET) and near-infrared fluorescence. Radionuclide and fluorescent tracers that identify inflammation, apoptosis and proteolysis, are promising. 17 A combination of activity of molecular processes and detailed anatomic information can be obtained, providing a powerful tool in the identification of the vulnerable plaque. With these developments, we are entering a new era of imaging techniques in the selection of patients for carotid surgery.
In routine clinical practice, the indication to treat using invasive techniques is usually based on 1 and 2, while the choice between carotid endarterectomy (CE) and carotid artery stenting (CS) is mainly based on 3, 4 and 5.
d. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.
Class II: Prospective matched group cohort study in a representative population with masked outcome assessment that meets a-d above OR a RCT in a representative population that lacks one criterion a-d. Class III: All other controlled trials (including welldefined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement. Class IV: Evidence from uncontrolled studies, case series, case reports, or expert opinion.
Classification of Recommendation
A = Established as effective, ineffective, or harmful for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.) B = Probably effective, ineffective, or harmful for the given condition in the specified population. (Level B rating requires at least one Class I study or at least two consistent Class II studies.) C = Possibly effective, ineffective, or harmful for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.) U = Data inadequate or conflicting; given current knowledge, treatment is unproven.
Medical Therapy
Atherosclerosis is a progressive systemic disease with strong relationships in the prevalence of plaques in different sites of arterial system. Carotid intima-media thickness (IMT) is a validated measure of atherosclerosis burden and is most reproducibly evaluated in the far wall of the distal common carotid artery 18 moreover, carotid atherosclerosis is a risk factor for several chronic diseases, including coronary artery disease 19 and stroke 20 . Carotid atherosclerotic plaque rupture is thought to cause transient ischemic attack and ischemic stroke. Pathological hallmarks of these plaques have been identified through observational studies.
Statins showed anti-atherosclerosis through pleiotropic effects. 21, 22 Statin significantly reduces the progression of early, preintrusive atherosclerosis. A trend for reduction in carotid IMT was shown after only 6 months of therapy. 23 Aggressive statins were more −0.063 mm/y of reduction in annual progression of carotid atherosclerosisthan conventional statins therapy. 24 The latest recommendations for primary prevention of stroke from the European Stroke Organization are that blood cholesterol should be checked regularly; high cholesterol (e.g., LDL cholesterol >3.9 mmol/L [150 mg/dL]) should be managed with lifestyle modification (class IV, level C) and a statin (class I, level A). In secondary prevention of stroke, statin therapy is recommended for patients with non-cardioembolic stroke (class I, level A). 25 In secondary prevention of stroke, evidence-based data from the only available trial were obtained with a high dose of atorvastatin (80 mg per day 26 ); post-hoc analysis of the subgroup of patients with Heart Protection Study (HPS) who had a previous stroke found no effect on stroke recurrence with simvastatin 20-40 mg per day. 27 An analysis from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed that lowering of LDL cholesterol concentrations to less than 1.8 mmol/L compared with more than 2.6 mmol/L (70 vs 100 mg/dL) was followed by a 28% reduction in relative risk for stroke. 28 This result was obtained post-hoc and, therefore, is hypothesis generating. The next step would be to show that, in patients with a stroke or transient ischaemic attack, an LDL cholesterol concentration of less than 1.8 mmol/L (70 mg/dL) is associated with a lower incidence of recurrent stroke or other major vascular events than is a concentration of less than 2.6 mmol/L (100 mg/dL).
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β-blocker can reduce the rate of carotid intima media thickness progression in clinically healthy, symptomfree subjects with carotid plaque 30 , the results suggest that the autonomic nervous system may be an important role in atherosclerosis development in otherwise healthy people with carotid plaque. Secondary stroke prevention after transient ischemic stroke or minor stroke is of major importance in order to avoid recurrent cerebrovascular events and decrease morbidity and mortality.
For patients with non-cardioembolic stroke, antiplatelet agents are the treatment of choice. Aspirin (81 to 325 mg) plus extended-release dipyridamole and clopidogrel are more effective than aspirin and should be used in patients with a high risk of recurrent stroke. 31 Oral anticoagulations are highly effective in patients with a cardiac source of embolism. Medical therapy alone is preferred for patients in whom the risk of revascularization outweighs its benefits, including patients who are at low risk for stroke with medical therapy (symptomatic stenosis less than 50%, asymptomatic stenosis less than 60%), and those with a highrisk of procedure-related stroke or death due to clinical or technical factors. Patients with transient ischemic attack (TIA) / minor stroke should be seen as soon as possible in dedicated centers that offer single visit imaging. All patients should start taking their risk factor medications as soon as possible and patients with a 50 -99% ipsilateral internal carotid artery stenosis should be transferred to the Vascular clinic for further managements. 
Carotid artery stenting
Carotid angioplasty and stenting (CS) has steadily developed over the preceding decade. The main advantages of CS over CE are that the procedure is less invasive, performed under local anaesthesia, and is less influenced by the co-morbidities of the patient, while the outcomes are determined mainly by anatomical or procedural variables. [32] [33] [34] The disadvantages of CS are (1) it is not suitable if there is a contrast allergy, severe aortic arch atheroma, highly tortuous arteries or lumenthrombus (2) femoral artery puncture is required, which may cause a cutaneous or femoral nerve injury, and a wound haematoma which may become infected or compress vital groin structures (3) higher total procedural costs due to more expensive devices used for endovascular treatment (4) it may cause a stroke, as a result of arterial dissection, late embolization of thrombus on damaged plaque, hypotension (carotid sinus stimulation), aneurysm formation, or arterial puncture (5) uncertain durability over many years in preventing ipsilateral carotid ischemic stroke. Although no randomized study has compared carotid angioplasty vs. stenting, virtually all endovascular carotid procedures currently performed are stentbased. Carotid stents are self-expanding and the vast majority of them are made of nitinol.
Patients undergoing CS are commonly pre-treated with aspirin and clopidogrel. Aspirin is continued lifelong and clopidogrel given for at least 1 month after the procedure. The concept of dual antiplatelet therapy came from the coronary experience and was immediately embraced by part of the interventional community also for the endovascular treatment of the carotid arteries. Small randomized trials comparing single with double antiplatelet therapy for CS followed but had to be prematurely terminated due to high stent thrombosis and neurological event rates in the aspirinonly group. 35 The first randomized trial comparing endovascular and surgical treatments for carotid stenosis patients, CAVATAS (Carotid and Vertebral Artery Transluminal Angioplasty Study) 36 , which was published in 2001, included 504 patients enrolled between 1992 and 1997 and was designed to compare balloon angioplasty alone versus CE. Stents, when they became available, were incorporated as well but only accounted for 26% of cases. The CAVATAS trial demonstrated no statistically significant difference between endovascular and surgical treatment in the rate of disabling stroke or death within 30 days (6.4% CS vs. 5.9% CE) and no significant difference in the 3-year ipsilateral stroke rate. These early encouraging results generated a great deal of interest in CS, and further studies were undertaken. The long-term effectiveness of endovascular treatment of this trial reported in 2009. 37 Patients who were randomly assigned in CAVATAS and completed treatment for carotid stenosis (200 patients had endovascular treatment and 213 patients had CE) had prospective clinical follow-up at a median of 5 years and carotid duplex ultrasound at a median of 4 years. Severe carotid restenosis (≥70%) or occlusion occurred significantly more often in patients in the CS than in patients in the CE (adjusted hazard ratio [HR] 3.17, 95% CI 1.89 -5.32; p<0·0001). The estimated 5-year incidence of restenosis was 30.7% in the CS and 10.5% in the CE. Patients in the endovascular arm who were treated with a stent (n=50) had a significantly lower risk of developing restenosis of 70% or greater compared with those treated with balloon angioplasty alone (n=145; HR 0.43, 0.19-0.97; p=0·04). Current smoking or a history of smoking was a predictor of restenosis of 70% or more (2.32, 1.19-4.54; p=0·01) and the early finding of moderate stenosis (50 -69%) up to 60 days after treatment was associated with the risk of progression to restenosis of 70% or more (3.76, 1.88 -7.52; p=0·0002). There were more patients with non-perioperative ipsilateral stroke or transient ischaemic attack (HR 1.29, 95% CI 0.78 -2.14) and more patients with non-perioperative ipsilateral stroke (1.22, 0.59 -2.54) in the endovascular arm than there were in the endarterectomy arm during follow-up, although these differences were not statistically significant. The increase in events in the endovascular arm might be partly explained by the high incidence of restenosis after endovascular treatment.
Hassan Murad M., et al. in 2008 performed systemic review and meta-analysis compared CE vs CS for carotid artery stenosis. 38 Ten randomized controlled trials (RCTs) with 3182 participants proved eligible, provided low to moderate quality evidence. At 30 days and compared with CE, CS was associated with a nonsignificant reduction in the risk of death in five studies (RR, 0.61; 95% CI, 0.27-1.37; I 2 = 0%); a nonsignificant reduction in the risk of nonfatal MI in 3 studies (RR, 0.43; 95% CI, 0.17-1.11; I 2 = 0%); and a nonsignificant increase in the risk of any stroke in 5 studies (RR, 1.29; 95% CI, 0.73-2.26; I 2 = 40%). When only major and disabling strokes were included in the analysis, a similar nonsignificant increase in the risk of stroke was noted in patients who received CS in 4 studies (RR, 1.06; 95% CI, 0.32-3.52; I2 = 45%). When only Q-wave myocardial infarctions (MIs) we reincluded in analysis, data were very limited and precluded meaningful analysis (1 Q-wave MI in the CS group vs 4 in the CE group). These results came from only two trials, because the other trials did not differentiate between Q and non-Q wave MI. These analysis limitations are blind of data in each study and half of the trials were stopped early and yielded imprecise results on the outcome of stroke, which is the main outcome these two procedures are primarily intended to prevent. Finally, both procedures appear equivalent on their effects on death and nonfatal MI; the difference in risk of strokes between procedures remains inconclusive, with a trend toward superiority favoring CE. 39 The European Society for Vascular Surgery (ESVS) again brought together a group of experts in the field of carotid artery disease to produce updated guidelines for the invasive treatment of carotid disease in 2009. 40 The available level I evidence suggests that for symptomatic patients, surgery is currently the best option [A]. Mid-term stroke prevention after successful CS is similar to CE [A]. CS should be offered to symptomatic patients, if they are at high risk for CE, in highvolume centers with documented low peri-procedural stroke and death rates or inside an RCT [C].
CS is a reasonable alternative to CE, particularly in patients at high risk for CE. The concept of a high-risk patient is very controversial. It appears that when patients meet North American Symptomatic Carotid Endarterectomy Trial (NASCET) / the Asymptomatic Carotid Atherosclerosis Study (ACAS) exclusion criteria, they are automatically defined as high risk.
The Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy trial (SAPPHIRE) is the only randomized trial comparing CS and CE performed with the systematic use of Embolic Protection Devices (EPDs). 41 The trial included symptomatic and asymptomatic patients at high risk for surgery and wasdesigned to prove the noninferiority of the endovascularapproach. According to the SAPPHIRE trial, a high-risk patient with medical co-morbidities has one of the following features:
1. congestive heart failure (New York Heart Association class III/IV) and/or a known severe left ventricular dysfunction; 2. open heart surgery needed within 6 weeks; 3. recent MI; 4. unstable angina (Canadian Cardiovascular Society class III/IV); or 5. severe pulmonary disease.
Barbato J. E., et al. in 2008 performed a prospective, randomized, single-center study of CS with or without a distal cerebral protection filter. 42 A 1:1 scheme was used to randomize 36 carotid artery stenting procedures in 35 patients. Diffusion-weighted magnetic resonance imaging 24 hours after stenting was used to assess the occurrence of new embolic lesions. Four strokes occurred (11%), two in each group, in patients aged 75, 80, 82, and 84 years.
They concluded that the use of filters during CS provided no demonstrable reduction of microemboli. However Garg N., et al. in 2009 performed a random effects meta-analysis of studies with concurrently reported data on protected and unprotected CS. 43 Initial database queries resulted in 2485 articles, of which 134 were included in the final analyses (12,263 protected CAS patients and 11,198 unprotected CS patients). Using pooled analysis of all 134 reports, the relative risk (RR) for stroke was 0.62 (95% CI 0.54 to 0.72) in favor of protected CS. Subgroup analysis revealed a significant benefit for protected CS in both symptomatic (RR 0.67; 95% CI 0.52 to 0.56) and asymptomatic (RR 0.61; 95% CI 0.41 to 0.90) patients (p<0.05).
Zarins C. K., et al. in 2009 reported a prospective, nonrandomized comparative cohort study of a broad-risk population of symptomatic and asymptomatic patients with carotid stenosis namely "Carotid revascularization using endarterectomy or stenting systems" (CaRESS). 44 There were 397 patients enrolled (254 underwent CE and 143 underwent protected CS). More than 90% of patients had >75% stenosis; two thirds were asymptomatic. The risk of death or nonfatal stroke 4 years following CS with distal protection is equivalent to CE in a broad category of patients with carotid stenosis. There were no significant differences in stroke or mortality rates between high-risk and nonhigh-risk patients and no differences in outcomes between symptomatic and asymptomatic patients. After 4 years, CS had a 2-fold higher restenosis rate compared to CE. The risk of death/ stroke or death/stroke/MI appears to be higher following CE than CS among patients <80 years of age, yet there is no statistically significant relationship between death, stroke, or MI among octogenarians.
Asymptomatic Carotid Surgery Trial-2 (ACST-2) is a randomized clinical trial comparing carotid endarterectomy with carotid artery stenting in patients with asymptomatic carotid artery stenosis. At least 5000 patients with asymptomatic carotid stenosis are thought to be needed to participate. It will provide important evidence comparing the immediate and long-term safety and efficacy of CE and CS in patients with asymptomatic carotid stenosis.
Carotid Endarterectomy
Generally, treatment for symptomatic carotid stenosis is settled with interventions such as either CS or CE. However treatments for asymptomatic carotid stenosis are controversial. Symptomatic patients with moderate stenosis of the carotid artery (50-69% stenosis), or intraplaque hemorrhage demonstrated by MRI is a good indicator of recurrent ipsilateral stroke and TIA and may be used to improve patient selection for carotid surgery. 45 In the Asymptomatic Carotid Surgery Trial (ACST), the annual risk of stroke after CE (0.55%) was much less than the annual risk with the Best Medical Treatment (BMT) alone (1.9%). 46 Both the Asymptomatic Carotid Atherosclerosis Study (ACAS) and ACST studies compared CE plus BMT versus BMT alone, and both studies demonstrated a decreased risk of stroke by approximately 50% at 5 years. 47 The current guideline recommendation Table 1 ) for asymptomatic patient is to perform CE in asymptomatic men with <75 years of age with 70-99% stenosis, if the perioperative stroke and death rate is <3%. CE should be considered in younger, fit women. When CE is used in combination with BMT and performed well, it can have life-long protective effects against stroke-related death and disability for patients with asymptomatic carotid stenosis. Several trials compared "best medical treatment (BMT)" vs CS vs CE. [48] [49] [50] Abbott was one of the first to observe that the annual risk of stroke in medically treated patients has declined significantly over the last 20 years and the latest metaanalysis concludes that non-interventional therapy is the safer option, whilst also being more costeffective. 48 A second (smaller) meta-analysis published in 2010 included natural history data from three studies recruiting after 2000 and found that the average annual risk of ipsilateral stroke in 1635 medically treated patients was 0.5%. 53 Abbott and others have attributed this decline in stroke risk to improvements in BMT, especially through the use of high dose statins. 54, 55 Not surprisingly, this has elicited the inevitable counterargument, primarily because some studies in Abbott's meta-analysis included patients with 50-99% as opposed to 60-99% stenoses.
Since there is a trend of reduction of incidence of stroke over the years after improvement of medical treatments, we need to undertake an adequately powered randomized trial which includes treatment arms for CE, CS and BMT. This should make it possible to test algorithms for identifying 'high risk for stroke' subgroups (e.g., transcranial Doppler embolisation, silent infarction on CT, incomplete circle of Willis, computerised plaque morphology, biomarkers).
The CE is absolutely indicated in symptomatic patients with >70% (NASCET) stenosis [A] and probably with >50% (NASCET) stenosis [A] . The perioperative stroke/death rate should be <6%. CE is contraindicated for symptomatic patients with less than 50% stenosis [A] . CE should be performed within 2 weeks of the patient's last symptoms [A] .
There is still considerable controversy with regard to the role of prophylactic CE in coronary artery bypass grafting (CABG) patients with coexistent carotid artery disease. In many centres around the world, the detection of a carotid stenosis greater than 70% (irrespective of neurological symptom status) will prompt either synchronous or staged CE plus CABG. A 2003 systematic review of 8972 patients undergoing synchronous or staged CEA and CABG identified three studies (99 patients) where in CE was performed immediately prior to off-pump coronary artery bypass grafting (OPCAB) with a reported 30-day death/stroke rate of 1.0%. 56, 57 This was considerably less than comparable reported risks for patients undergoing synchronous CE plus On-Pump CABG [30-day death/ stroke 8.7% (95% confidence interval (CI): 7.7-9.8)], staged CE-CABG [30-day death/stroke 6.1% (95% CI: 2.9-9.3)] and reverse-staged On-Pump CABG-CE [30-day death/stroke rate 7.3% (95% CI: 1.7-12.9)]. 58 In relation to the peripheral vascular disease, the prevalence of internal carotid artery stenosis of 70% in patients with peripheral vascular disease was 24.7%. 59 Age, smoking quantity and a carotid bruit were independent risk factors associated with severe carotid stenosis. Routine duplex screening is recommended in patients with peripheral vascular disease, particularly in male, elderly smokers. 52 CE recommended in asymptomatic men with <75 years of age with 70-99% stenosis, if the perioperative stroke and death rate is <3%. CE should be considered in younger, fit women. 40 
Society / Association Recommnedation
The following are MRA (Figure 1 ), endarterectomy specimen (Figure 2 a, b) and CE with vein patch (Figure 3 ) in one of our patients. This patient recovered well without any complication; however he would face a higher risk of stroke if CS was performed.
Major Recommendations
1. Carotid endarterectomy (CE) is established as effective for recently (within previous 6 months) symptomatic patients with 70 to 99% internal carotid artery (ICA) angiographic stenosis (Level A). CE should not be considered for symptomatic patients with less than 50% stenosis (Level A). CE may be considered for patients with 50 to 69% symptomatic stenosis (Level B) but the clinician should consider additional clinical and angiographic variables (Level C, see below). It is recommended that the patient have at least a 5-year life expectancy and that the perioperative stroke/death rate should be <6% for symptomatic patients (Level A). Medical management is preferred to CE for symptomatic patients with <50% stenosis (Level A).
2. It is reasonable to consider CE for patients between the ages of 40 and 75 years and with asymptomatic stenosis of 60 to 99% if the patient has an expected 5-year life expectancy and if the surgical stroke or death frequency can be reliably documented to be <3% (Level A). The 5-year life expectancy is important since perioperative strokes pose an up front risk to the patient and the benefit from CE emerges only after a number of years.
3. No recommendation can be provided regarding the value of emergent CE in patients with a progressing neurologic deficit (Level U).
Contraindications to CE are carotid stenosis at surgically inaccessible sites, recurrent stenosis after previous endarterectomy, and stenosis after irradiation. Cervical irradiation is a known risk factor for accelerating carotid stenosis progression. Carmody et al. demonstrated a 22% prevalence of >70% carotid stenosis in patients with previous neck radiotherapy compared with 4% in controls. 60 Eighty percent of patients with significant stenosis in the irradiated group were symptomatic. CE in these patients is hindered by previous surgical reconstructions and radiation-induced fibrosis that obliterates the endarterectomy plane and, as a result, is often associated with interposition graft placement. CE in these patients is not associated with a greater risk of stroke; however, a higher incidence of arterial damage, cranial nerve palsy, prosthetic infection, anastomotic breakdown, restenosis, and an increased rate of wound complications have been reported. 61 Octogenarians alone are not a contraindication for CE. Octogenarians undergoing CS had a 3.46-times higher absolute risk of stroke than those undergoing CE. CS in octogenarians using current technology should be avoided in favor of CE or possibly medical management unless a stroke rate of less than 3% can be achieved.
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Bangkok Medical Center's Experience
The incidence of carotid artery stenosis in Thailand is currently unknown; however we estimated it would increase together with the increasing incidence of coronary artery disease in Thailand. The number of patients who underwent CE at the Bangkok Medical Center has increased over the year since K.T. started a CE program. 4. Clinicians should consider patient variables in CE decision making. Women with 50 to 69% symptomatic stenosis did not show clear benefit in previous trials. In addition, patients with hemispheric transient ischemic attack (TIA)/stroke had greater benefit from CE than patients with retinal ischemic events (Level C). Clinicians should also consider several radiologic factors in decision making about CE. For example, contralateral occlusion erases the small benefit of CE in asymptomatic patients whereas in sympto atic patients, it is associated with increased operative risk but persistent benefit (Level C). CE for patients with angiographic nearocclusion in symptomatic patients is associated with a trend toward benefit at 2 years but not associated with a clear long-term benefit (Level C). Patients operated on within 2 weeks of their last TIA or mild stroke derive greater benefit from CE (Level C).
5. Symptomatic and asymptomatic patients undergoing CE should be given aspirin (81 or 325 mg/day) prior to surgery and for at least 3 months following surgery to reduce the combined endpoint of stroke, myocardial infarction, and death (Level A). Although data are not available, it is recommended that aspirin (81 or 325 mg/ day) be continued indefinitely provided that contraindications are absent. Aspirin at 650 or 1300 mg/day is less effective in the perioperative period.
6. At this time the available data are insufficient to declare either CE before or simultaneous with coronary artery bypass graft (CABG) as superior in patients with concomitant carotid and coronary artery occlusive disease (Level U).
7. For patients with severe stenosis and a recent TIA or nondisabling stroke, CE should be performed without delay, preferably within 2 weeks of the patient's last symptomatic event (Level C). There is insufficient evidence to support or refute the performance of CE within 4 to 6 weeks of a recent moderate to severe stroke (Level U).
Conclusion
Intensive medical treatments are absolute indicated in all patients with carotid disease. CE currently remains the first choice of revascularisation therapy for an asymptomatic carotid lesion in most treament centres. For symptomatic patients, CE is much safer than CS, particularly for patients older than 70 years. CS might be considered for patients with limited access to surgery or for difficult technical surgery.
